AssayIndex
Tissue-repair and immunomodulatory peptides

ARA-290

cibinetide · Helix B surface peptide · C50H83N15O18 · monoisotopic 1189.6096 Da. The index holds 65 assay reports on this compound across 13 batches from 10 suppliers.

65 reports13 batchesmedian 99.45 %index spec 98.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

An 11-residue linear peptide with an uneventful assay; the index tracks it chiefly because its supplier coverage is unusually even, which makes it a useful control compound when comparing supplier medians. If a supplier's ARA-290 median sits well below its semaglutide median, the difference is unlikely to be assay difficulty and more likely to be process control on short peptides.

Molecular formula
C50H83N15O18
Monoisotopic mass
1189.6096Da
Average mass
1190.30Da
Residues
11
Nominal retention (RG-2, 30 min)
8.72min
Retention window
0.25min
Counter-ion as usually shipped
acetate
Typical label claims
2 mg · 4 mg · 10 mg
Analytical difficulty (index scale)
0.90 — straightforward
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

030806160923912319 ARA-2908.72 min · 99.45 % 8.50 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative ARA-290 trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 99.45 % area at the nominal retention time of 8.72 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 65 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 99.45% n=65
Interquartile range 0.85pp n=65
Minimum 97.96% n=65
Maximum 99.93% n=65
Pass rate vs spec 98.5% n=65
Median recovery vs claim 95.4% n=34
Median water 4.24% n=65
Median |mass error| 3.0ppm n=55
08162492.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=097.75–98.00 %: n=198.00–98.25 %: n=098.25–98.50 %: n=598.50–98.75 %: n=498.75–99.00 %: n=599.00–99.25 %: n=799.25–99.50 %: n=1199.50–99.75 %: n=799.75–100.00 %: n=25median 99.45 Purity (% area) Reports
Figure 2. Purity distribution across all 65 ARA-290 records. Dashed line is this compound's median (99.45 %); the solid vertical is the index acceptance specification for the tissue-repair and immunomodulatory peptides class (98.0 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.898.298.698.999.399.7100.1TFCTFC: Q1 99.54, median 99.82, Q3 99.93, n=17n=17GGPepsGGPeps: Q1 98.83, median 99.03, Q3 99.33, n=11n=11WWBWWB: Q1 99.81, median 99.93, Q3 99.93, n=10outlier 99.42outlier 99.45n=10JEEPJEEP: Q1 98.79, median 99.02, Q3 99.12, n=8outlier 99.63n=8WXTWXT: Q1 98.72, median 99.18, Q3 99.34, n=7n=7QYBQYB: Q1 99.58, median 99.83, Q3 99.93, n=5outlier 98.46n=5HomopeptideHomopeptide: Q1 99.66, median 99.74, Q3 99.84, n=3n=3SGNSGN: Q1 98.11, median 98.27, Q3 98.42, n=2n=2 Purity (% area)
Figure 3. ARA-290 purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
deamidated (+1 Da)-0.22+0.98491%0.131.03
acetyl adduct (+42 Da)+0.40+42.01188%0.090.74
des-Gln truncate (−128 Da)-0.30-128.05982%0.110.67
[D-Ser]-diastereomer-0.12mass-identical77%0.100.55

Degradation pathways

  • Asn/Gln deamidation
  • no oxidative liability

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Cibinetide has been studied in sarcoidosis-associated small-fibre neuropathy; phase 2 results were reported in 2019 and no product is approved.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q30n<3—
2024-Q41099.8199.25–99.93
2025-Q10n<3—
2025-Q21499.4198.49–99.93
2025-Q30n<3—
2025-Q41699.1798.36–99.93
2026-Q11399.9398.86–99.93
2026-Q21299.0297.96–99.93
2026-Q30n<3—

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent ARA-290 records of 65.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041852JEEPJEEP-2601-K3139Janoshik2026-Q299.034.60—Buyer-sourced1MARGINAL
AX-2026-043211SGNSGN-2605-X9661PeptideMeter2026-Q297.967.11101.7Supplier-supplied1FAIL
AX-2026-041857JEEPJEEP-2601-K3139Kestrel2026-Q299.094.21—Supplier-supplied1MARGINAL
AX-2026-043212SGNSGN-2605-X9661PeptideMeter2026-Q298.587.00—Supplier-supplied1MARGINAL
AX-2026-041853JEEPJEEP-2601-K3139PeptideMeter2026-Q298.504.5194.7Laboratory-retained1MARGINAL
AX-2026-041856JEEPJEEP-2601-K3139Janoshik2026-Q299.634.2992.0Supplier-supplied1MARGINAL
AX-2026-041851JEEPJEEP-2601-K3139Janoshik2026-Q299.004.51—Supplier-supplied1MARGINAL
AX-2026-041858JEEPJEEP-2601-K3139VendorInvestigate2026-Q298.824.14—Buyer-sourced1MARGINAL
AX-2026-041855JEEPJEEP-2601-K3139Janoshik2026-Q299.214.41—Supplier-supplied1MARGINAL
AX-2026-041854JEEPJEEP-2601-K3139VendorInvestigate2026-Q298.693.84107.0Buyer-sourced1MARGINAL
AX-2026-042123HomopeptideHOMO-2601-T8238Medutest2026-Q299.933.40102.7Supplier-supplied0PASS
AX-2026-042122HomopeptideHOMO-2601-T8238Nordanalyt2026-Q299.573.7490.6Buyer-sourced1MARGINAL
AX-2026-041317WWBWWB-2511-S3009Janoshik2026-Q199.934.60—Supplier-supplied0PASS
AX-2026-041313WWBWWB-2511-S3009Nordanalyt2026-Q199.934.81—Supplier-supplied0PASS
AX-2026-042751GGPepsGGPE-2602-W9566Medutest2026-Q198.862.1793.9Supplier-supplied1MARGINAL
AX-2026-041322WWBWWB-2511-S3009Janoshik2026-Q199.935.26—Supplier-supplied0PASS
AX-2026-042179HomopeptideHOMO-2602-K9510PeptideMeter2026-Q199.744.19103.7Supplier-supplied1MARGINAL
AX-2026-041314WWBWWB-2511-S3009PeptideMeter2026-Q199.454.87—Laboratory-retained1MARGINAL
AX-2026-041320WWBWWB-2511-S3009Janoshik2026-Q199.425.13—Laboratory-retained1MARGINAL
AX-2026-041316WWBWWB-2511-S3009Janoshik2026-Q199.795.17—Supplier-supplied0PASS
AX-2026-041315WWBWWB-2511-S3009PeptideMeter2026-Q199.934.8398.4Supplier-supplied0PASS
AX-2026-042354HJHJ-2508-C4013PeptideMeter2026-Q199.934.51—Supplier-supplied0PASS
AX-2026-041321WWBWWB-2511-S3009Janoshik2026-Q199.934.6493.0Supplier-supplied0PASS
AX-2026-041318WWBWWB-2511-S3009Medutest2026-Q199.934.44107.4Supplier-supplied0PASS
AX-2026-041319WWBWWB-2511-S3009PeptideMeter2026-Q199.885.1089.2Supplier-supplied2MARGINAL